Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer

PLoS ONE(2024)10.1371/journal.pone.0305710Source: DataRank Database

Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer is a research paper published in PLoS ONE (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 0.16)OA: goldTopics (41)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Ssu-Hsueh Tseng,Hua-Ling Tsai,Vikrant Palande,Michelle A. Rudek ORCID,Richard B.S. Roden ORCID

Live enrichment

PubMed:38990850 PMC:PMC11239005 OpenAlex:https://openalex.org/W4400526829

Congressionally Directed Medical Research Programs

Grant: OC210370

National Cancer Institute

Grant: P50CA098252

National Cancer Institute

Grant: P50CA228991

National Cancer Institute

Grant: P30CA006973

National Center for Advancing Translational Sciences

Grant: UL1TR003098

National Cancer Institute

Grant: 1S10RR026824-01

UPLC with Tandem MS for Sensitive Quantitative Analysis of Small Molecules

National Institutes of Health

Grant: 5P50CA228991-02

SPORE in Ovarian Cancer

National Institutes of Health

Grant: 5P50CA098252-17

SPORE in Cervical Cancer

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

National Institutes of Health

Grant: 5UL1TR003098-02

Johns Hopkins Institute for Clinical and Translational Research

FWCI

0.16

Citation Percentile

0.5%

Citation Trend

2025

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0305710&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0305710&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0305710

journalhttps://doi.org/10.1371/journal.pone.0305710

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38990850

Fields of Study

Ubiquitin and proteasome pathwaysProtein Degradation and InhibitorsPeptidase Inhibition and Analysis

MeSH Terms

Carcinoma, Ovarian EpithelialAnimalsAntineoplastic AgentsFemaleGuanidinesHumansOvarian NeoplasmsSpiro CompoundsXenograft Model Antitumor AssaysCell Line, TumorIntracellular Signaling Peptides and ProteinsMice

Keywords

ChemistryOvarian cancerPharmacologyGuanidineCancer researchBiochemistryCancerBiologyMedicineInternal medicineOvarian NeoplasmsScienceQRIntracellular Signaling Peptides and ProteinsAntineoplastic AgentsCarcinoma, Ovarian EpithelialXenograft Model Antitumor AssaysGuanidinesMiceCell Line, TumorAnimalsHumansFemaleSpiro CompoundsResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer

FAIR Checklist

Authors (6)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)